Elotuzumab in ELOQUENT-2 trial for relapsed/refractory multiple myeloma- AbbVie + BMS

The addition of elotuzumab, from AbbVie + BMS, with lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed/refractory multiple myeloma, according to interim results from the 646 patient, phase III ELOQUENT-2 trial. The data, which were presented during a presscast held in advance of the 2015 ASCO Annual Meeting, showed that combining the monoclonal antibody with standard care prolonged remission by 4.5 months.

Comment: Elotuzumab showed a progression free survival (PFS) of 4.5 months over the Revlimid/dexamethasone combination.( 19.4 months v. 14.9 months at 2 years) and an overall response rate of 41% v. 27% at 2 years( P= 0.0001). Seen as "somewhat modest" effect.The PFS of elotuzumab was slightly lower than Kyprolis in a similar designed trial.